EUA sa Sinopharm vaccine, posibleng ilabas na ng FDA sa susunod na linggo

By Chona Yu May 27, 2021 - 01:51 PM

FILE PHOTO: A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang

Maaring magpalabas na ng emergency use authorization (EUA) sa loob ng linggong ito o sa susunod na linggo ang Food and Drug Administration (FDA) para sa bakuna kontra COVID-19 na gawa ng Sinopharm.

Sa report ni FDA director general Eric Domingo, sinabi nito na naghihintay na lamang sila ng kaunting dokumento mula sa Department of Health (DOH).

Mayo 20 nang mag-apply ang DOH ng EUA sa FDA para sa Sinopharm.

Ayon kay Domingo, base sa evaluation ng mga eksperto, paborable ang nakukuhang review ng Sinopharm.

“Iyon pong Sinopharm nag-apply na rin po ang DOH noong May 20, last week din po and patapos na rin po iyong ano ang evaluation ng mga experts natin sa data na nakuha natin, it’s — and it seems to be very favorable. Mayroon na lang pong kaunting documents na isa-submit po ang DOH sa atin and we believe that we will be able to ano also complete evaluation and issue an EUA for Sinopharm either towards the end of this week or early next week,” pahayag ni Domingo.

Matatandaang Sinopharm ang ginamit na bakuna kay Pangulong Rodrigo Duterte at sa mga miyembro ng Presidential Security Group (PSG).

TAGS: COVID-19 vaccination, eric domingo, EUA Sinopharm, FDA, Inquirer News, Radyo Inquirer news, Sinopharm vaccine, COVID-19 vaccination, eric domingo, EUA Sinopharm, FDA, Inquirer News, Radyo Inquirer news, Sinopharm vaccine

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.